logo

Ra Pharmaceuticals, Inc. (RARX)



Trade RARX now with
  Date
  Headline
2/27/2020 7:25:04 AM Ra Pharma Q4 Net Loss $36.8 Mln Or $0.79/Shr Vs Net Loss Of $16.2 Mln Or $0.47/Shr Last Year
2/18/2020 7:06:56 AM Ra Pharma Announces Publication Of Zilucoplan Phase 2 GMG Trial Results In JAMA Neurology
1/22/2020 9:08:40 AM Ra Pharma Announces Clearance Of IND Application For HEALEY ALS Platform Trial
12/4/2019 7:05:14 AM Ra Pharma Announces Dosing Of First Patient In Phase 2 Clinical Trial Of Zilucoplan For IMNM
10/10/2019 1:25:04 AM UCB To Acquire Ra Pharma For $48 Per Share In Cash
10/2/2019 7:14:18 AM Ra Pharmaceuticals Begins Dosing In RAISE Study
9/4/2019 7:03:38 AM Ra Pharma Receives Orphan Drug Designation From FDA For Zilucoplan For Myasthenia Gravis
4/24/2019 6:35:13 AM Ra Pharmaceuticals Presents Pre-Clinical Data For Zilucoplan XR At The 6th Annual Peptides Congress
4/9/2019 7:04:23 AM Ra Pharma Announces Completion Of End-of-Phase 2 Interactions With FDA And Design Of Pivotal Phase 3 GMG Study
3/7/2019 7:34:30 AM Ra Pharma Q4 Net Loss $16.2 Mln Or $0.47/shr Vs Loss $15.1 Mln Or $0.67/Shr Last Year
12/11/2018 6:33:08 PM Ra Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
12/10/2018 4:01:28 PM Ra Pharmaceuticals Announces Proposed Public Offering Of Common Stock
12/10/2018 7:04:31 AM Ra Announces Positive Top-line Data From Phase 2 Trial Of Zilucoplan In Patients With Generalized Myasthenia Gravis
12/6/2018 7:32:32 AM Ra Pharma Gets Development Milestone Payment Under Its Collaboration Agreement With Merck